Femasys (NASDAQ:FEMY) Stock Price Expected to Rise, HC Wainwright Analyst Says

Femasys (NASDAQ:FEMY) had its price objective upped by HC Wainwright from $12.00 to $15.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Femasys Stock Performance

Shares of NASDAQ FEMY traded up $0.04 during midday trading on Wednesday, hitting $1.58. The company’s stock had a trading volume of 371,559 shares, compared to its average volume of 264,004. The firm has a market capitalization of $36.18 million, a price-to-earnings ratio of -1.98 and a beta of -2.85. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86. The stock has a fifty day moving average price of $1.34 and a 200 day moving average price of $1.20. Femasys has a one year low of $0.86 and a one year high of $2.07.

Hedge Funds Weigh In On Femasys

A number of large investors have recently made changes to their positions in FEMY. XTX Topco Ltd raised its stake in shares of Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after purchasing an additional 18,004 shares during the period. Geode Capital Management LLC grew its holdings in Femasys by 9.2% during the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after buying an additional 17,473 shares in the last quarter. Virtu Financial LLC purchased a new position in Femasys during the 4th quarter valued at about $25,000. Northern Trust Corp increased its position in shares of Femasys by 42.6% during the fourth quarter. Northern Trust Corp now owns 126,096 shares of the company’s stock valued at $139,000 after buying an additional 37,675 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of Femasys in the fourth quarter valued at approximately $30,000. 65.27% of the stock is owned by institutional investors.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.